Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
-0.14 (-17.95%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Acer Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 1 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 25 | 17 | 23 | 30 |
Income After Depreciation & Amortization | 0 | -25 | -16 | -23 | -30 |
Non-Operating Income | NA | -2 | 1 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -26 | -15 | -23 | -29 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -26 | -15 | -23 | -29 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -26 | -15 | -23 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -25 | -16 | -23 | -30 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -25 | -16 | -23 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 15.77 | 14.27 | 11.12 | 10.09 |
Diluted EPS Before Non-Recurring Items | NA | -1.60 | -1.08 | -2.06 | -2.91 |
Diluted Net EPS (GAAP) | NA | -1.66 | -1.08 | -2.06 | -2.91 |
Fiscal Year end for Acer Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | 0.37 | 0.00 |
Cost Of Goods | NA | NA | NA | 0.08 | 0.00 |
Gross Profit | NA | NA | NA | 0.29 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 13.16 | 4.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | -12.87 | -4.29 |
Non-Operating Income | NA | NA | NA | -1.85 | -3.80 |
Interest Expense | NA | NA | NA | 0.00 | 0.00 |
Pretax Income | NA | NA | NA | -14.73 | -8.09 |
Income Taxes | NA | NA | NA | 0.00 | 0.00 |
Minority Interest | NA | NA | NA | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | NA | 0.00 | 0.00 |
Other Income/Charges | NA | NA | NA | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | NA | -14.73 | -8.09 |
Extras & Discontinued Operations | NA | NA | NA | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | NA | -14.73 | -8.09 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 24.46 | 24.46 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -0.53 | -0.23 |
Diluted Net EPS (GAAP) | NA | NA | NA | -0.60 | -0.33 |